European life sciences investment group LSP said yesterday it closed its new $330 million (EU €280 million) medical technology fund.
The new Health Economics Fund 2 was oversubscribed and exceeded its target size and original hard cap, LSP said. The investment group touted the fund as the largest in Europe to be dedicated to medical technology.
“With this new and sizable fund, we have now firmly established our health economics and medical technology strategy. Together with our other fund strategies, LSP 1-5 investing mainly in drug development and LSP Public investing in public health care companies, we now cover the entire life sciences landscape as one of Europe’s largest investors in the sector,” LSP managing partner Dr René Kuijten said in a prepared statement.
The newly formed LSP HEF 2 fund will look to invest in private companies with innovative medical devices, diagnostics and digital health, LSP said. The first HEF fund previously made 10 investments in the same field, with notable investments in Neuravi and Rotation Medical.
The LSP HEF 2 will focus on Europe and the US and aims to invest in approximately 15 private companies across the areas of medical devices, diagnostics and digital health.
“The success of this fundraising is a strong validation of our strategy – investing in medical innovation to benefit both patients, and investors. As with the first LSP Health Economics Fund, we plan to invest in companies with products that can improve quality of care and lower healthcare spending. Our portfolio companies not only contribute to the sustainability of today’s healthcare systems, they also tend to be highly successful in the market, leading to fast adoption and making them attractive acquisition targets. Success stories like Neuravi and Rotation Medical from the first LSP Health Economics Fund are great examples of how our strategy can combine the best patient care with superior returns to our investors. We look forward to continuing this investment strategy with LSP HEF 2,” LSP HEF 2 managing partner Dr Rudy Dekeyser said in a press release.